A Single-center, Open-label, Randomized, Two-treatment Crossover Study to Investigate the Effect of Selexipag on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Selexipag (Primary) ; Midazolam
- Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 12 Jun 2017 Results published in the European Journal of Clinical Pharmacology
- 12 Oct 2016 Status changed from recruiting to completed.
- 21 Jul 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.